Literature DB >> 17078485

Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance.

Guylaine Haché1, Louis M Mansky, Reuben S Harris.   

Abstract

Over 40 million people worldwide currently have HIV/AIDS. Many antiretroviral drugs have proven effective, but drug-resistant HIV variants frequently emerge to thwart treatment efforts. Reverse transcription errors undoubtedly contribute to drug resistance, but additional significant sources of viral genetic variation are debatable. The human APOBEC3F and APOBEC3G proteins can potently inhibit retrovirus infection by a mechanism that involves retroviral cDNA cytosine deamination. Here we review the current knowledge on the mechanism of APOBEC3-dependent retrovirus restriction and discuss whether this innate host-defense system actively contributes to HIV genetic variation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17078485

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  34 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

4.  Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Soo-Yon Rhee; Nicolas Eriksson; Tommy F Liu; Mark Kiuchi; Amar K Das; Robert W Shafer
Journal:  AIDS       Date:  2008-03-30       Impact factor: 4.177

Review 5.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

Review 6.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

7.  Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif.

Authors:  Kara G Lassen; Silke Wissing; Michael A Lobritz; Mario Santiago; Warner C Greene
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

8.  An Alu Element Insertion in Intron 1 Results in Aberrant Alternative Splicing of APOBEC3G Pre-mRNA in Northern Pig-Tailed Macaques (Macaca leonina) That May Reduce APOBEC3G-Mediated Hypermutation Pressure on HIV-1.

Authors:  Xiao-Liang Zhang; Meng-Ting Luo; Jia-Hao Song; Wei Pang; Yong-Tang Zheng
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

9.  A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins.

Authors:  Gajendra W Suryawanshi; Alexander Hoffmann
Journal:  J Theor Biol       Date:  2015-09-16       Impact factor: 2.691

10.  Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance.

Authors:  Patric Jern; Rebecca A Russell; Vinay K Pathak; John M Coffin
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.